Nanocraft, a Serbian biotech startup focused on early detection of cardiovascular disease, has secured €175,000 in funding from TS Ventures Fund, positioning itself for significant growth in a rapidly evolving industry.
Information on the Target
Nanocraft is an innovative startup operating in the biotech sector, focusing on the early detection of plaque in blood vessels, which is critical for preventing cardiovascular diseases. Currently in its infancy, the company shows significant potential for global expansion as it develops its technology further.
In its initial funding round, Nanocraft has successfully raised €175,000, assigning it a pre-money valuation of €1,000,000. The founder, who has an educational background in France and Canada, made the thoughtful decision to return to Serbia to lead this promising venture, despite opportunities to remain abroad.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Serbia
The Serbian biotech industry is in a growth phase, spurred by increased investment in research and development, as well as favorable government policies aimed at f
Similar Deals
Elaia, Pfizer Ventures, Bpifrance → Enodia Therapeutics
2026
Cardumen Capital → Biographica
2026
Kurma Partners, WE Life Sciences, Bpifrance, Argobio, Angelini Ventures, CARMA Fund, Capital Grand Est, Sambrinvest → Elkedonia
2025
TS Ventures Fund
invested in
Nanocraft
in 2024
in a Seed Stage deal
Disclosed details
Transaction Size: $0M
Enterprise Value: $1M
Equity Value: $1M